Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details

FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer Clinical Trial ( IRB ) #: U26-286-1 Title: FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer Principal Investigator: Dr. Jennifer Jorgensen Description: The purpose of this research study is to learn more about sofetabart mipitecan also known as Sofe-M or LY4170156. Sofe-M is a new investigational drug under investigation in this study for the treatment of ovarian, primary peritoneal, or fallopian tube cancers. Classification:   Cancer - Female Reproductive Eligibility Criteria: Check with study contact How to Contact: Jillian Mcnamara Telephone: Telephone: 860-679-4581. Email: jimcnamara@uchc.edu Enrollment Status/Comments: Enrolling/recruiting.